Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and passing protection through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the vaccine safeguards at-risk babies

RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine works by stimulating the mother’s body’s defences to produce defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the moment of birth, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches approximately 85% when the vaccine is administered at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide meaningful protection, with evidence indicating that a fortnight’s interval is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to have the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.

• Nearly 85% protection when vaccinated 4 weeks before birth
• Maternal antibodies transferred through the placenta safeguard newborns from birth
• Protection achievable with 2-week gap before early delivery
• Vaccination during the third trimester still offers significant infant protection

Strong evidence from recent research

The performance of the pregnancy RSV vaccine has been confirmed through a comprehensive study conducted across England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that six-month period, providing comprehensive and reliable data of the vaccine’s actual performance. The study’s results have been supported by the UK Health Security Agency as showing strong protection for newborns during their earliest and most vulnerable period. The breadth of this investigation offers healthcare professionals and prospective parents with trust in the vaccine’s demonstrated effectiveness across varied populations and settings.

The results reveal a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This marked difference underscores the vaccine’s vital importance in preventing serious illness in newborns. The reduction in hospital admissions exceeding 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings support the importance of the vaccination programme launched in the UK in 2024.

Research approach and coverage

The research reviewed birth and hospitalisation records from England over a six-month timeframe, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to establish direct comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and reflective of the wider population, rather than individual cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had received the vaccine at different timepoints before delivery. This allowed researchers to identify the shortest interval needed between vaccination and birth for best possible protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing real-world data of how the vaccine works when administered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.

Learning about RSV and its dangers

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.

The infection produces deep inflammation in the lungs and airways, making it extremely challenging for vulnerable newborns to breathe and feed properly. Parents often witness their babies struggling visibly, their chests heaving as they work to get enough air into their compromised lungs. Whilst the majority of babies improve through palliative treatment, a limited though important number die from RSV-related complications each year, making vaccination as prevention a essential public health priority for protecting the most vulnerable and youngest individuals in the population.

• RSV produces inflammation in lungs, resulting in serious respiratory problems in infants
• Approximately half of infants contract the virus in their first few months of life
• Symptoms range from minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
• More than 20,000 UK infants require serious hospital care for RSV each year
• Small numbers of babies die from RSV related complications each year in the UK

Take-up rates and specialist advice

Since the RSV vaccine programme began in 2024, health officials have stressed the importance of pregnant women receiving their jab at the optimal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing matters greatly for guaranteeing newborns receive the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies transferred to their babies via the placenta.

The communication from public health bodies remains clear: pregnant women should make a priority of vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This adaptable strategy acknowledges the realities of pregnancy and childbirth whilst maintaining strong safeguarding for at-risk infants during their most critical early months when RSV represents the highest danger of severe infection.

Regional disparities in vaccine uptake

Whilst the RSV vaccine programme has been rolled out across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to boost understanding and access to the jab. These regional differences reflect variations in healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data shows consistently strong protection irrespective of geographical location.

• NHS trusts rolling out varied communication campaigns to connect with women during pregnancy
• Inconsistencies across regions in vaccine uptake rates in different parts of England necessitate strategic intervention
• Community health services tailoring initiatives to suit local requirements and situations

Practical implications and parental perspectives

The vaccine’s outstanding effectiveness provides tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the rollout of this protective measure, the 80% drop in admissions equates to thousands of infants protected against serious illness. Parents no longer face the upsetting situation of watching their newborns gasping for air or labour to feed, symptoms that mark critical RSV illness. The vaccine has markedly changed the landscape of neonatal respiratory health, providing expectant mothers a proactive tool to shield their most at-risk babies during those vital initial period.

For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s availability carries deep personal significance. His mother’s advocacy for the jab highlights the transformative consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to expectant mothers navigating their late pregnancy, changing what was once an predictable seasonal threat into a manageable risk.